Get the Stockscreener App
4.09
2.25%
0.09
After Hours:
4.08
-0.010
-0.24%
Cytomx Therapeutics Inc stock is traded at $4.09, with a volume of 1.31M.
It is up +2.25% in the last 24 hours and up +0.00% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$4.00
Open:
$3.96
24h Volume:
1.31M
Relative Volume:
0.37
Market Cap:
$692.99M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-204.50
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
-3.08%
1M Performance:
+0.00%
6M Performance:
+62.95%
1Y Performance:
+217.05%
1-Day Range:
$3.94
$4.1985
1-Week Range:
$3.655
$4.325
52-Week Range:
$0.40
$4.62
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.09 | 677.74M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
Will CytomX Therapeutics Inc. (6C1) stock sustain dividend payoutsJuly 2025 Sector Moves & Verified Short-Term Plans - Newser
Will CytomX Therapeutics Inc. stock beat EPS estimatesForecast Cut & Capital Efficient Trade Techniques - Newser
Published on: 2025-12-04 08:11:15 - Newser
Why CytomX Therapeutics Inc. (6C1) stock is listed among top recommendationsMarket Activity Summary & Capital Protection Trade Alerts - Newser
Is CytomX Therapeutics Inc. (6C1) stock ideal for retirement investorsJuly 2025 Patterns & Fast Gain Stock Trading Tips - Newser
What insider purchases suggest about CytomX Therapeutics Inc. (6C1) stockFed Meeting & Fast Gain Stock Trading Tips - Newser
Is CytomX Therapeutics Inc. (6C1) stock a buy on weaknessQuarterly Trade Summary & Fast Entry High Yield Tips - Newser
Will CytomX Therapeutics Inc. (6C1) stock outperform Dow JonesSell Signal & High Return Stock Watch Alerts - Newser
How CytomX Therapeutics Inc. (6C1) stock reacts to weak economy2025 Price Targets & Entry Point Confirmation Alerts - Newser
Portfolio Shifts: Is CytomX Therapeutics Inc 6C1 stock undervalued by metricsWeekly Loss Report & Daily Technical Stock Forecast Reports - BỘ NỘI VỤ
Is CytomX Therapeutics Inc. stock a contrarian buyWeekly Trend Report & Daily Technical Forecast Reports - Newser
Will CytomX Therapeutics Inc. (6C1) stock benefit from infrastructure billWeekly Volume Report & High Conviction Buy Zone Picks - Newser
Is CytomX Therapeutics Inc. (6C1) stock suitable for passive index fundsTrade Volume Summary & Risk Controlled Stock Pick Alerts - Newser
Why CytomX Therapeutics Inc. (6C1) stock is a strong buy callQuarterly Profit Report & Daily Market Momentum Tracking - Newser
What analyst consensus says on CytomX Therapeutics Inc. stockMarket Performance Summary & Risk Managed Trade Strategies - Newser
Revenue per share of CytomX Therapeutics, Inc. – DUS:6C1 - TradingView
Is CytomX Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Decliners & Real-Time Volume Analysis Alerts - BỘ NỘI VỤ
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN
CTMX (CytomX Therapeutics) Other Income (Minority Interest) : $0.0 Mil (TTM As of Sep. 2025) - GuruFocus
CX-2051 Momentum and An Expanding Oncology Pipeline Strengthen CytomX Therapeutics’ (CTMX) Investment Case - Insider Monkey
Will CytomX Therapeutics Inc. stock recover faster than peers2025 Historical Comparison & Fast Entry High Yield Tips - BỘ NỘI VỤ
Is CytomX Therapeutics Inc. (6C1) stock attractive for dividend growthJuly 2025 Snapshot & Technical Pattern Based Buy Signals - moha.gov.vn
Can CytomX Therapeutics Inc. stock sustain free cash flow growth2025 Price Targets & Weekly Watchlist for Hot Stocks - BỘ NỘI VỤ
Will CytomX Therapeutics Inc. stock split attract more investors2025 Key Lessons & Long-Term Growth Portfolio Plans - BỘ NỘI VỤ
ON Partners Recruits Chief Business Officer for CytomX Therapeutics - Hunt Scanlon Media
CytomX Therapeutics to Present at Upcoming December Investor Conferences - The Manila Times
CytomX Therapeutics (NASDAQ: CTMX) joins Evercore, Piper Sandler healthcare investor conferences in December - Stock Titan
Why Analysts Say the CytomX Story Is Evolving After Recent Clinical Momentum and Price Target Hike - Yahoo Finance
CytomX Therapeutics (CTMX) Price Target Increased by 15.12% to 7.21 - MSN
CytomX Therapeutics Inc Stock Analysis and ForecastVolume Profile Analysis & Superior Portfolio Investment - earlytimes.in
Will CytomX Therapeutics Inc. stock deliver consistent dividendsTrade Entry Report & Expert Curated Trade Setup Alerts - newser.com
Will CytomX Therapeutics Inc. stock see insider buyingEarnings Overview Summary & Low Risk High Reward Ideas - newser.com
Why CytomX Therapeutics Inc. (6C1) stock gets analyst attentionExit Point & High Accuracy Buy Signal Tips - newser.com
CTMX (CytomX Therapeutics) Price-to-Operating-Cash-Flow : (As of Nov. 20, 2025) - GuruFocus
CytomX at Jefferies Conference: Promising Cancer Treatment Insights By Investing.com - Investing.com Canada
CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
Is CytomX Therapeutics Inc. stock a bargain at current levelsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com
What technical charts say about CytomX Therapeutics Inc. stockJuly 2025 Fed Impact & Free Verified High Yield Trade Plans - newser.com
Is CytomX Therapeutics Inc. (6C1) stock attractive post correctionGap Up & Weekly Setup with High ROI Potential - newser.com
How CytomX Therapeutics Inc. (6C1) stock behaves in tightening cyclesRecession Risk & Low Drawdown Investment Ideas - newser.com
CTMX (CytomX Therapeutics) Dividend Payout Ratio : 0.00 (As of Sep. 2025) - GuruFocus
CTMX (CytomX Therapeutics) Short-Term Debt : $0.0 Mil (As of Sep. 2025) - GuruFocus
CTMX (CytomX Therapeutics) Accounts Payable & Accrued Expen - GuruFocus
Can CytomX Therapeutics Inc. stock beat analyst upgrades2025 Market Overview & Weekly High Potential Stock Alerts - newser.com
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):